Brokerages Set Applied Therapeutics Inc. (NASDAQ:APLT) PT at $6.10

Key Points

• Applied Therapeutics Inc. (NASDAQ:APLT) received a consensus rating of “Moderate Buy” from six brokerages, with three analysts suggesting a hold and three recommending a buy.
• The average one-year price target for the stock among these brokers is $6.10, significantly above its current trading price of $0.48.
• Institutional investors hold 98.31% of the company's stock, with notable recent increases in holdings from multiple firms, including a 132.2% increase by CreativeOne Wealth LLC.

Shares of Applied Therapeutics Inc. (NASDAQ:APLT - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $6.10.

A number of research analysts recently commented on APLT shares. Royal Bank Of Canada restated a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th.

Institutional Trading of Applied Therapeutics

Several large investors have recently made changes to their positions in the business. CreativeOne Wealth LLC grew its holdings in Applied Therapeutics by 132.2% during the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock worth $25,000 after acquiring an additional 28,701 shares during the last quarter. Ground Swell Capital LLC bought a new stake in shares of Applied Therapeutics during the fourth quarter valued at approximately $27,000. Toronto Dominion Bank bought a new position in Applied Therapeutics in the fourth quarter valued at about $27,000. Dark Forest Capital Management LP boosted its stake in shares of Applied Therapeutics by 54.5% in the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after purchasing an additional 18,949 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in Applied Therapeutics in the fourth quarter valued at approximately $49,000. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Stock Performance

Shares of Applied Therapeutics stock traded up $0.00 during trading on Monday, reaching $0.43. The company's stock had a trading volume of 397,632 shares, compared to its average volume of 2,790,421. The business's fifty day moving average price is $0.39 and its 200-day moving average price is $0.46. The firm has a market cap of $61.44 million, a price-to-earnings ratio of -1.01 and a beta of 1.82. Applied Therapeutics has a one year low of $0.30 and a one year high of $10.62.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.